Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of sirolimus when given together with cisplatin and gemcitabine hydrochloride and to see how well they work in treating patients with bladder cancer. Biological therapies, such as sirolimus, may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sirolimus together with cisplatin and gemcitabine hydrochloride may be an effective treatment for bladder cancer.
Detailed description
PRIMARY OBJECTIVES: I. To define the maximum-tolerated dose (MTD) of sirolimus (rapamycin) combined with gemcitabine hydrochloride and cisplatin (GC). (Phase I) II. To determine the pathologic complete response rate at cystectomy in patients with localized, muscle invasive carcinoma of the bladder (clinical tumor \[T\]2-4, node \[N\]0 or N1). (Phase II) SECONDARY OBJECTIVES: I. To assess the response rate to rapamycin combined with GC. (Phase I) II. To assess effect of rapamycin with GC on deoxyribonucleic acid (DNA) damage surrogates in cancer associated stroma compared to untreated and GC treated stroma. (Phase I) III. To assess effect of rapamycin with GC on DNA damage surrogates in cancer associated stroma compared to untreated and GC treated stroma. (Phase II) IV. To assess toxicity of the MTD dose of rapamycin with GC. (Phase II) OUTLINE: This is a phase I, dose de-escalation study of sirolimus followed by a phase II study. Patients receive sirolimus orally (PO) two hours before or after grapefruit juice on day -2, cisplatin intravenously (IV) on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients undergo cystectomy as clinically appropriate after 1-4 courses of treatment. After completion of study treatment, patients are followed up for 28 days.
Interventions
DRUGCisplatin
Given IV
DRUGGemcitabine Hydrochloride
Given IV
DRUGSirolimus
Given PO
PROCEDURECystectomy
Undergo cystectomy when appropriate
Sponsors
National Cancer Institute (NCI)
University of Washington
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information * Histologically or cytologically confirmed carcinoma of the bladder of all histologies except neuroendocrine differentiation or squamous cell histology * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1 * Eligibility for phase 1 and phase 2 components: * Phase 1 - clinical T3 or T4 or N1 or M1 cancer which is untreated or previously treated with platinum based therapy with primary tumor still present in the bladder and amenable to sampling before and after treatment, as indicated * Phase 2 - clinical T2-4 N0 or N1 untreated with primary tumor still present in the bladder and amenable to sampling before and after treatment, as indicated * Life expectancy \>= 12 weeks * No prior malignancy is allowed except: * Adequately treated basal cell or squamous cell skin cancer or * In situ carcinoma of any site or * Other adequately treated malignancy for which the patient is currently disease free for at least one year * Absolute neutrophil count \>= 1.5 x 10\^9 cells/L * Hemoglobin (Hgb) \>= 9.0 g/dL * Platelets \>= 100,000 x 10\^9/L * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =\< 1.5 x upper limit of normal (ULN) * Bilirubin and total bilirubin levels =\< 1.5 x ULN * Serum creatinine \< 1.5 X institutional ULN mg/dL OR glomerular filtration rate (GFR) \>= 50 mL/min * All pre-study labs required for determination of eligibility are to be completed within 30 days prior to day -2 (or the next business day if falls on a weekend or holiday) * X-rays and/or scans to assess all disease sites are to be completed within 30 days prior to day -2 (or the next business day if falls on a weekend or holiday)
Exclusion criteria
* Patients currently receiving active therapy for other neoplastic disorders * Known parenchymal brain metastasis * Active or symptomatic viral hepatitis or chronic liver disease * Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of \< 45 % at baseline, if done * Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy * Administration of an investigational therapeutic within 30 days of cycle 1, day 1 * Patients with dementia/psychiatric illness/social situations that would limit compliance with study requirements or would prohibit the understanding and/or giving of informed consent * Patients with medical conditions, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained will not be eligible * Any condition which, in the opinion of the investigator, would preclude participation in this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients With Dose Limiting Toxicity | Up to 28 days | Safety will be assessed through summaries of adverse events, vital signs, physical examinations, and clinical laboratory test data (including change from baseline). |
| Percent of Patients With Pathologic Complete Response (Phase II) | 12 weeks | The study will follow an optimal two-stage Simon design based on pathologic complete response rate. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events Including Any Unfavorable and Unintended Sign, Symptom, Diagnosis, or Disease Temporally Associated With the Use of a Medicinal Product, Whether or Not Related to the Medicinal Product (Phase I and II) | Up to 28 days after completion of study treatment | Graded according to the NCI CTCAE version 4.0. Safety will be assessed through summaries of adverse events, vital signs, physical examinations, and clinical laboratory test data (including change from baseline). All adverse events resulting in discontinuation, dose modification, dosing interruption, and/or treatment delay of study drug will also be listed and tabulated by preferred term. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Sirolimus, Cisplatin, Gemcitabine Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
Cisplatin: Given IV
Gemcitabine Hydrochloride: Given IV
Sirolimus: Given PO
Cystectomy: Undergo cystectomy when appropriate | 21 |
| Total | 21 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lack of Efficacy | 1 | 0 |
| Overall Study | Operation at other hospital | 1 | 0 |
Baseline characteristics
| Characteristic | Sirolimus, Cisplatin, Gemcitabine | — |
|---|---|---|
| Age, Continuous | 69 years | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment United States | 21 participants | — |
| Sex: Female, Male Female | 1 Participants | — |
| Sex: Female, Male Male | 20 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 21 |
| other Total, other adverse events | 21 / 21 |
| serious Total, serious adverse events | 0 / 21 |
Outcome results
Primary
Patients With Dose Limiting Toxicity
Safety will be assessed through summaries of adverse events, vital signs, physical examinations, and clinical laboratory test data (including change from baseline).
Time frame: Up to 28 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1 - Sirolimus, Cisplatin, Gemcitabine | Patients With Dose Limiting Toxicity | 0 Participants |
Primary
Percent of Patients With Pathologic Complete Response (Phase II)
The study will follow an optimal two-stage Simon design based on pathologic complete response rate.
Time frame: 12 weeks
Population: Patients treated in phase 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1 - Sirolimus, Cisplatin, Gemcitabine | Percent of Patients With Pathologic Complete Response (Phase II) | 4 Participants |
Secondary
Incidence of Adverse Events Including Any Unfavorable and Unintended Sign, Symptom, Diagnosis, or Disease Temporally Associated With the Use of a Medicinal Product, Whether or Not Related to the Medicinal Product (Phase I and II)
Graded according to the NCI CTCAE version 4.0. Safety will be assessed through summaries of adverse events, vital signs, physical examinations, and clinical laboratory test data (including change from baseline). All adverse events resulting in discontinuation, dose modification, dosing interruption, and/or treatment delay of study drug will also be listed and tabulated by preferred term.
Time frame: Up to 28 days after completion of study treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1 - Sirolimus, Cisplatin, Gemcitabine | Incidence of Adverse Events Including Any Unfavorable and Unintended Sign, Symptom, Diagnosis, or Disease Temporally Associated With the Use of a Medicinal Product, Whether or Not Related to the Medicinal Product (Phase I and II) | 45 Number of events |